1,064 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
JNJ Johnson & Johnson $139.96 $375.48B N/A
Article Searches
J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View http://www.zacks.com/stock/news/382057/jj-jnj-beats-on-q1-earnings-ups-2019-sales-growth-view?cid=CS-ZC-FT-382057 Apr 16, 2019 - J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
J&J (JNJ) Tops Q1 Earnings; Pharma Segment Drives Sales http://www.zacks.com/stock/news/381300/jj-jnj-tops-q1-earnings-pharma-segment-drives-sales?cid=CS-ZC-FT-381300 Apr 16, 2019 - J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019. Hikes 2019 guidance for operational sales and earnings growth. Shares up in pre-market trading.
JNJ up 1% premarket on Q1 beat https://seekingalpha.com/news/3450947-jnj-1-percent-premarket-q1-beat?source=feed_news_all Apr 16, 2019 - Johnson & Johnson (JNJ) Q1 results: Revenues: $20,021M (+0.1%); Consumer: $3,318M (-2.4%); Pharmaceuticals: $10,244M (+4.1%); Medical Devices: $6,459M (-4.6%).Net Income: $3,749M (-14.2%); EPS: $1
Q1 Earnings To Watch For http://www.zacks.com/stock/news/382036/q1-earnings-to-watch-for?cid=CS-ZC--382036 Apr 16, 2019 - Q1 Earnings To Watch For
Q1 Earnings Spigot Opens: JNJ, BAC, UNH & More http://www.zacks.com/stock/news/381535/q1-earnings-spigot-opens-jnj-bac-unh-more?cid=CS-ZC-FT-381535 Apr 16, 2019 - This is the first "full week" of Q1 earnings season, though the influx of reports hitting the tape in the next few weeks to come will be even heavier.
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer http://www.zacks.com/stock/news/380671/jjs-erdafitinib-gets-fda-approval-for-urothelial-cancer?cid=CS-ZC-FT-380671 Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal http://www.zacks.com/stock/news/379777/pharma-stock-roundup-azn-mrk-gsk-get-regulatory-approvals-sandoz-inks-new-deal?cid=CS-ZC-FT-379777 Apr 12, 2019 - Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Looking for a Growth Stock? 3 Reasons Why Johnson & Johnson (JNJ) is a Solid Choice http://www.zacks.com/stock/news/379548/looking-for-a-growth-stock-3-reasons-why-johnson-johnson-jnj-is-a-solid-choice?cid=CS-ZC-FT-379548 Apr 12, 2019 - Johnson & Johnson (JNJ) could produce exceptional returns because of its solid growth attributes.
What's in Store for Dow ETF in Q1 Earnings? http://www.zacks.com/stock/news/378730/whats-in-store-for-dow-etf-in-q1-earnings?cid=CS-ZC-FT-378730 Apr 11, 2019 - Let's delve into the Q1 earnings picture that will likely set up the movement of the Dow Jones ETF in the coming days.
Alkermes Reports Positive Data From Schizophrenia Study http://www.zacks.com/stock/news/377786/alkermes-reports-positive-data-from-schizophrenia-study?cid=CS-ZC-FT-377786 Apr 10, 2019 - Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.

Pages: 123456789...107

<<<Page 4>